Drugs in MeSH Category Bronchoconstrictor Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193-002	Aug 29, 2016		DISCN	Yes	No
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193-001	Oct 31, 1986		RX	Yes	Yes

Market dynamics and patent landscape for drugs in NLM MeSH Class: Bronchoconstrictor Agents

Last updated: April 26, 2026

Drugs classified under NLM MeSH: Bronchoconstrictor Agents span prescription and over-the-counter therapies used to prevent or treat bronchospasm and bronchial obstruction, with the majority of patentable value concentrated in inhaled β2-agonists, anticholinergics, leukotriene-pathway drugs, and selective airway-directed agents rather than in the broncho-provocative compounds that primarily exist in research or emergency settings.

What’s in the MeSH “Bronchoconstrictor Agents” bucket?

MeSH “Bronchoconstrictor Agents” is a broad umbrella that includes pharmacologic agents that constrict bronchial smooth muscle or trigger bronchoconstriction, plus related airway-state modifiers that sit in adjacent therapeutic workflows (as indexed in MeSH). Market value is driven mainly by drugs whose clinical role is to manage bronchospasm (not induce it) because those are sold at chronic scale in asthma and COPD. Sales concentration tends to occur in inhalation platforms with strong generics pressure after expiry, while patentable innovation clusters around formulation, delivery, and patient-specific dosing convenience.

Where is revenue concentrated across bronchoconstrictor-related therapies?

The spend is concentrated in airway bronchodilators used in obstructive lung disease. Even when a drug’s mechanistic label intersects “bronchoconstriction,” clinicians and payers primarily transact on reliever and controller bronchodilation and anti-inflammatory leukotriene-axis control.

Revenue drivers (market structure)

1. Inhaled delivery dominates because it improves lung exposure and reduces systemic adverse effects versus oral dosing.
2. Formulation and device IP often extends effective exclusivity through:
   • new particle engineering for inhaler deposition,
   • fixed-dose combinations,
   • device-integrated dosing algorithms and cartridge designs.
3. Patent cliff behavior is consistent: innovator brands see volume erosion within 3 to 6 years of key patent expiry, with faster erosion in molecules with multiple approved generic entrants.

Competitive intensity by therapy type

Therapy type (common bronchospasm-management use)	Main patentable leverage	Typical competition pattern after expiry
Short-acting β2-agonists (SABA)	Formulation/device	Rapid generic entry, pricing compression
Long-acting β2-agonists (LABA)	Molecular patents, then delivery combo patents	Moderate-to-strong generic uptake
Long-acting muscarinic antagonists (LAMA)	Molecular patents, inhaler platforms	Strong generic pressure post-expiry
LABA/LAMA fixed-dose combinations	Combination and device patents	Clustered generics with multiple NDCs
Leukotriene-pathway drugs (e.g., CysLT1 antagonists)	Scaffold patents, extended formulations	Generics expand steadily
Airway-targeted bronchodilator delivery innovations	Device and formulation	Patent thickets, slower copy where device is central

What are the current patent dynamics for bronchoconstrictor-related drugs?

Patent landscapes for this class typically show:

• Core composition-of-matter (C-MOF) patents for the active ingredient(s),
• Method-of-use patents that target specific dosing patterns, subpopulations, or combination regimens,
• Formulation and delivery patents that protect inhaled particle size, suspension stability, and inhaler mechanics,
• Combination patents for fixed-dose regimens (especially LABA/LAMA, and LABA/inhaled steroid or leukotriene/bronchodilator combos, when covered by MeSH-adjacent indexing).

Typical exclusivity timeline mechanics (practical)

• Primary patent expiry: usually the last broad composition and is the first major cliff.
• Secondary patents: method-of-use and formulation can extend market exclusivity by 2 to 5 years in certain jurisdictions, depending on claim scope and regulatory exclusivity linkage.
• Device/formulation thickets: multiple overlapping continuations and reissues can delay generic “design-around” acceptance.

MeSH-adjacent patent landscape themes by drug family

Because the MeSH umbrella is mechanistically broad, the most actionable way to map the landscape is by mechanism families that dominate commercial bronchospasm control.

β2-agonists (SABA and LABA)

• Patent leverage: composition-of-matter for the molecule, followed by delivery improvements and fixed-dose combination strategies.
• Landscape pattern: older molecules face extensive generic penetration; later LABA molecules and combo products show more layered exclusivity.

Anticholinergics (LAMA and combinations)

• Patent leverage: molecular IP and inhaler platform IP.
• Landscape pattern: strong post-expiry generic activity, with some delay where device engineering and dosing control are protected.

Leukotriene pathway agents

• Patent leverage: C-MOF for the scaffold plus controlled-release or pediatric dosing patents.
• Landscape pattern: steady generics expansion, less dependent on device complexity than inhaled β2/LAMA products.

Airway smooth muscle contraction-related agents (bronchoconstrictors as indexed in MeSH)

• Commerciality: lower chronic market scale; more frequent use in challenge testing, research, or emergency bronchospasm scenarios.
• IP pattern: fewer large blockbuster product portfolios; where IP exists, it can be protected by legacy patents and formulation specificity rather than device ecosystems.

How does market structure affect patent strategy?

Bronchospasm management is an “infrastructure” market: once payers, prescribers, and inhaler handling workflows standardize around a brand or device, switching costs rise, which changes patent strategy.

Key behavioral drivers:

• Form-factor lock-in: device handling and patient training create switching inertia.
• Guideline inertia: product positioning in asthma and COPD step therapy drives sustained use even as competitors launch substitutes.
• Payer formularies: narrow coverage windows can extend effective exclusivity even after legal expiry if generics launch later, or if switching requires prior authorization.

Patent landscape: what matters to a business evaluator

A credible pipeline or BD screen requires focusing on:

1. Which claims are likely enforceable post-challenge (C-MOF vs formulation vs method-of-use).
2. Whether the competitor’s generics or authorized generics can “design around” delivery claims.
3. Whether exclusivity has regulatory hooks that attach to the same product or device.

Enforceability hotspots in this therapeutic area

Claim type	Typical strength in this class	Key risk for innovator
Composition-of-matter	High for truly novel scaffolds	Early generic entry if claims are narrow or if multiple alternatives exist
Formulation and delivery	Medium-to-high when device coupling is essential	Generics can use alternative inhaler platforms if formulation claims are not platform-wide
Method-of-use	Medium; depends on claim clarity and evidence	Generic labeling carve-outs may preserve market share for authorized copies
Combination regimens	High if combination is tightly defined	Authorized generics and multi-source versions can fracture coverage

Where are the likely near-term patent cliffs and their market impact?

Across inhaled airway therapy, near-term cliffs typically concentrate around:

• older SABA and LABA molecules (first major wave),
• landmark LABA/LAMA fixed-dose combos (second wave),
• leukotriene-pathway agents (steady wave, often less device-dependent).

Market impact typically manifests as:

• price compression across NDCs,
• faster channel shifts in office-based prescribing where inhaler devices are standardized,
• higher share volatility during the 12 to 36 months surrounding expiry.

Business implications: investing or partnering in this class

1) Prioritize delivery and device IP where mechanism is mature

If the candidate is a known molecule, differentiation must come from:

• inhaler deposition engineering,
• particle size distribution stability,
• patient-centric dosing convenience,
• platform safety improvements that support broader labeling.

2) Map patent claims to actual switching pathways

Generic entry is constrained not only by composition patents but by:

• device claim obstacles,
• formulation compatibility with generic approvals,
• clinician and payer willingness to switch.

3) Treat combination products as separate patent battles

A combination’s patent life can diverge from the single-agent components due to:

• fixed-dose formulation and dosing regimen claims,
• patient-selection method-of-use patents,
• device and compatibility patents.

Key Takeaways

• MeSH “Bronchoconstrictor Agents” is broad, but commercial value sits primarily in bronchospasm management drugs used in asthma and COPD.
• Patent strategy in this class clusters around inhalation delivery and fixed-dose combinations, not only on composition-of-matter.
• Market dynamics are shaped by device lock-in, guideline step therapy, and payer formularies, making effective exclusivity often longer than the strict C-MOF expiry date.
• Patent cliffs typically translate into rapid pricing and share compression, with erosion speed dependent on whether generics can replicate protected formulation/device elements.
• For investment or BD screens, the most actionable target signals are device/formulation claim scope and combination regimen enforceability, not only the active ingredient’s primary patent.

FAQs

1) What portion of “Bronchoconstrictor Agents” is most commercially material?
Bronchospasm management drugs that function as bronchodilators and anti-leukotriene therapies dominate commercial scale; research broncho-provocative agents are comparatively niche.

2) Why do patents on inhaled bronchospasm therapies last longer in practice than composition patents alone?
Because formulation, particle engineering, device mechanics, and fixed-dose regimen claims create layered barriers to generic substitution and can delay switching.

3) Which claim types are most likely to influence generic launch timing?
Delivery/formulation claims and combination regimen definitions often control whether a generic can enter without infringement or without losing label acceptance.

4) How do payer and guideline behaviors affect patent value?
They create friction for switching, extending brand share even as legal exclusivity approaches expiry, and they can accelerate erosion once generics gain formulary access.

5) What’s the most important market metric to watch around patent expiry?
Speed of NDC-level share migration plus pricing compression rate across the affected inhaler/device platform, since those determine practical exclusivity duration.

---

References

[1] National Library of Medicine. Medical Subject Headings (MeSH). “Bronchoconstrictor Agents.” https://meshb.nlm.nih.gov/